Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VIRACEPT

« Back to Dashboard
Viracept is a drug marketed by Agouron and is included in three NDAs. It is available from five suppliers.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the nelfinavir mesylate profile page.

Summary for Tradename: VIRACEPT

Patents:0
Applicants:1
NDAs:3
Suppliers / Packagers: see list8

Pharmacology for Tradename: VIRACEPT

Drug ClassProtease Inhibitor
Mechanism of ActionHIV Protease Inhibitors

Clinical Trials for: VIRACEPT

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Status: Completed Condition: HIV Infection

Nelfinavir, a Phase I/Phase II Rectal Cancer Study
Status: Completed Condition: Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
Status: Recruiting Condition: Multiple Myeloma

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma
Status: Recruiting Condition: Myeloma

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
Status: Recruiting Condition: Non-Hodgkin Lymphoma; Hodgkin Lymphoma; Kaposi Sarcoma; Gastric Cancer; Nasopharyngeal Cancer; EBV; Castleman Disease

A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors
Status: Completed Condition: Solid Tumors

Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer
Status: Active, not recruiting Condition: Pancreatic Neoplasms

Radical Lung Radiotherapy Plus Nelfinavir
Status: Withdrawn Condition: Lung Cancer

Stereotactic Body Radiation With Nelfinavir for Oligometastases
Status: Recruiting Condition: Oligometastases

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer
Status: Completed Condition: Cervical Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Agouron
VIRACEPT
nelfinavir mesylate
POWDER;ORAL020778-001Mar 14, 1997DISCNNo<disabled><disabled>
Agouron
VIRACEPT
nelfinavir mesylate
TABLET;ORAL020779-001Mar 14, 1997RXYes<disabled><disabled>
Agouron
VIRACEPT
nelfinavir mesylate
TABLET;ORAL021503-001Apr 30, 2003RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc